

ForPatients

by Roche

CNS Tumors Brain Tumor Solid Tumors Cancer

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Trial Status

Active, not recruiting

Trial Runs In

11 Countries

Trial Identifier

NCT02650401 CO40778
RXDX-101-03

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

Hoffmann-La Roche

Sponsor

Phase 1

Phase

NCT02650401 CO40778 RXDX-101-03

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=0 Years & <= 18 Years

Healthy Volunteers

No